Kathleen M. Schmainda, PhD
MSEE, Electrical Engineering, MIT, 1989
PhD, Medical Engineering, Harvard-MIT, 1993
MA, Postdoctoral Fellowship in MRI, Massachusetts General Hospital, 1993-1995
Honors and Awards
1993-1994 - Sterling Winthrop Fellow, Health Sciences and Technology, Harvard-MIT, Cambridge, MA
1998 - Featured in Milwaukee Business Journal's "40 Under 40"
1999 - American Society of Neuroradiology Meeting, Magna Cum Laude, awarded to "Diffusion magnetic resonance imaging in stroke: A comparison of spin-echo and FLAIR spin echo diffusion sensitive techniques," JL Ulmer, AT Olson, LL Latour, OB Nordling, KM Donahue
2001 - 101st Annual Scientific Meeting of American Roentgen Ray Society, Seattle, Washington, Scientific Exhibit Gold Medal awarded to "Physiologic magnetic resonance imaging of the brain: A conceptual approach to contrast mechanisms and measureable physiologic parameters," JL Ulmer, JM Strottmann, RW Prost, KM Schmainda, BB Biswal, LP Mark, DL Daniels
2004 - International Society of Magnetic Resonance in Medicine Meeting, Young Investigator Moore Award, awarded to "Intravoxel distribution of DWI decay rates reveals C6 glioma invasion in rat brain," *KM Bennett, JS Hyde, SD Rand, R Bennett, HGJ Krouwer, KJ Rebro, KM Schmainda
2004 - International Society of Magnetic Resonance in Medicine Meeting, First Place Poster Award, Cancer Imaging and Spectroscopy, awarded to "The anti-angiogenic drug, SU11657 decreases brain tumor size and normalizes perfusion as indicated by DSC-MRI perfusion parameters," *CC Quarles, FC Wu, M Darpolor, SD Rand, HGJ Krouwer, KM Schmainda
2004 - American Society of Neuroradiology Meeting, Summa Cum Laude, awarded to "Lesion-induced neurovascular uncoupling can mimic cortical reorganization by BOLD fMRI," JL Ulmer, L Hacein-Bey, VP Mathews, EA DeYoe, RW Prost, KM Schmainda, WM Mueller, HGJ Krouwer
10/19/2007 - United States Patent (#6,807,441 B2) for “Evaluation of Tumor Angiogenesis Using Magnetic Resonance Imaging.” Inventor: KM Schmainda
6/2007 - Bayer Best Paper Award to Dr. Schmainda’s graduate student, Eric Paulson, at 45th Annual Meeting of American Society of Neuroradiology Meeting, Chicago, for “Correction of confounding leakage and residual susceptibility effects in dynamic susceptibility contrast MR imaging using dual-echo SPIRAL.” Authors: *ES Paulson, *D Prah, KM Schmainda
5/2008 - 3rd Place Poster Award to Dr. Schmainda’s graduate student, Douglas Prah, at 16th Annual Meeting of International Society of Magnetic Resonance in Medicine, Toronto, for “In vitro mitochondrial labeling using mito-carboxy proxyl (Mito-CP) enhanced magnetic resonance imaging.” Authors: *D Prah, *ES Paulson, J Zielonka, MJ Hardy, J Joseph, B Kalyanaraman, KM Schmainda
5/2009 - 1st Place Poster Award in Cancer Imaging, to Dr. Schmainda’s post-doctoral fellow, Dr. Elllingson, at 17th Annual Meeting for International Society of Magnetic Resonance in Medicine, Honolulu, for “Cytotoxic and anti-angiogenic treatment responses in gliomas using functional diffusion maps (fDMs) in FLAIR abnormal regions.” Authors: *B Ellingson, M Malkin, SD Rand, A Hoyt, J ConnellyJ, *B Bedekar, S Kurpad, KM Schmainda
7/28/2009 - United States Patent (#7,567,8321 B2) for “MRI method for measuring tumor hemodynamic parameters in the presence of contrast agent extravasation.” Inventors: KM Schmainda, C Quarles, BD Ward
8/27/2009 - United States Patent (#0214437-A1) for “In vivo mitochondrial labeling using positively-charged nitroxide enhanced gadolinium chelate magnetic resonance imaging.” Inventors: B Kalyanaraman, KM Schmainda, J Joseph, M Lopez, *D Prah, MJ Hardy
5/2010 - International Society of Magnetic Resonance in Medicine Meeting, Young Investigator Moore Award, awarded for “Validation of Functional Diffusion Maps (fDMs) as a Biomarker for Human Glioma Cellularity.” *BE Ellingson, MG Malkin, SD Rand, JM Connelly, C Quinsey, *PS LaViolette, *DP Bedekar, KM Schmainda
5/2012 - Merit Award, International Society of Magnetic Resonance in Medicine Meeting, awarded for “Precise ex-vivo histological validation of heightened cellularity in regions of dark ADC in three cases of high-grade glioma.” *PS LaViolette, E Cochran, M *Al-Gizawiy, S Rand, J Connelly, M Malkin, W Mueller, KM Schmainda
5/2013 - Summa Cum Laude Merit Award ISMRM Summa Cum Laude Merit Award, awarded for “The relationship between short and long diffusion time ADC values in rat brain tumors” *A Cohen, PS LaViolette, KM Schmainda, May 2013, p 0446.
10/2013 - United States Patent (#12/601,241) for “Multiparameter Perfusion Imaging with Leakage Correction”, Inventors: KM Schmainda, ES Paulson, D Prah, Issue Date: October 2, 2013
4/2016 - Elected to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows
9/2016-2018 - Robert C Olson MD Endowed Chair in Radiology, Medical College of Wisconsin, Milwaukee, WI. (Relinquished endowment in order to switch primary appointment to Biophysics.)
11/2016 - Distinguished Investigator of the Academy of Radiology Research, Radiological Society of North America, Chicago IL
8/28/2019 - Nominated as 1 of 16 semifinal candidates for “Most Influential Radiology Researcher” in the 2019 edition of the Minnies, AuntMinne.com (a large comprehensive community website for medical imaging professionals worldwide)
8/28/2019 - Nominated as 1 of 15 semifinal candidates nominated for “Scientific Paper of the Year” in the 2019 edition of the Minnies. The paper nominated is “Moving toward a consensus DSC-MRI protocol: Validation of a low-flip angle single-dose option as a reference standard for brain tumors.” Schmainda KM et al, American Journal of Neuroradiology, April 2019
9/5/2019 - Dean’s Award for Clinical and Translational Research 2019. Unanimously chosen to receive this prestigious award based on contributions to translational research and collaboration
11/20/2019 - Outstanding Graduate School Educator 2018-2019, MCW Graduate School of Biomedical Sciences
4/2020 - Elected as a Fellow of the International Society of Magnetic Resonance in Medicine
3/2020 - Awarded American Journal of Neuroradiology's Lucien Levy Best Research Article Award for the best original research paper accepted in 2019: J.M. Hoxworth, J.M. Eschbacher, A.C. Gonzales, K.W. Singleton, G.D. Leon, K.A. Smith, A.M. Stokes, Y. Zhou, G.L. Mazza, A.B. Porter, M.M. Mrugala, R.S. Zimmerman, B.R. Bendok, D.P. Patra, C. Krishna, J.L. Boxerman, L.C. Baxter, K.R. Swanson, C.C. Quarles, K.M. Schmainda, L.S. Hu. Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies. Am J Neurorad. Mar 2020, DOI: 10.3174/ajnr.A6486.
* Indicates student or staff under Dr. Schmainda
A primary focus of our laboratory is the development of MRI methods to assess brain tumor angiogenesis and invasion. Angiogenesis is the process of new vessel formation that enables tumors to grow and spread. Invasion describes the process whereby tumor cells enter and spread to other parts of the brain, making brain tumors very difficult to treat.
The methods developed in our laboratory can provide information about the normal brain and the vascular structure of tumors, the amount of blood volume in the brain and tumor (cerebral blood volume [CBV]), and the perfusion or delivery of blood to the tumor (cerebral blood flow [CB]). In addition, by using MRI methods capable of measuring the micromolecular movement of tissue water (i.e., diffusion), we have demonstrated the potential to track tumor progression and, possibly, invasion.
These vascular and diffusion parameters provide information about tumor biology that is not currently available with standard MRI used in clinical practice. Measurement of these parameters holds promise for providing a more complete assessment of the primary tumor and tumor spread, and for evaluating novel (e.g., anti-angiogenic) therapies. Studies performed in our laboratory address issues ranging from characterizing the basic biophysical relationships between the MRI signal and tumor biology to translating these methods to the clinical setting.
Cathy Marszalkowski, Clinical Research Coordinator II
Jaimy Pettit, Clinical Research Coordinator II
Melissa Prah, Engineer II
Robert Wujek, Graduate Student
Casey Zoss, Graduate Student
Advanced MR Techniques for Preoperative Glioma Characterization: Part 2.
(Hangel G, Schmitz-Abecassis B, Sollmann N, Pinto J, Arzanforoosh F, Barkhof F, Booth T, Calvo-Imirizaldu M, Cassia G, Chmelik M, Clement P, Ercan E, Fernández-Seara MA, Furtner J, Fuster-Garcia E, Grech-Sollars M, Guven NT, Hatay GH, Karami G, Keil VC, Kim M, Koekkoek JAF, Kukran S, Mancini L, Nechifor RE, Özcan A, Ozturk-Isik E, Piskin S, Schmainda KM, Svensson SF, Tseng CH, Unnikrishnan S, Vos F, Warnert E, Zhao MY, Jancalek R, Nunes T, Hirschler L, Smits M, Petr J, Emblem KE.) J Magn Reson Imaging. 2023 Jun;57(6):1676-1695 PMID: 36912262 SCOPUS ID: 2-s2.0-85150601586 03/14/2023
Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625.
(Boxerman JL, Snyder BS, Barboriak DP, Schmainda KM.) Front Oncol. 2023;13:1061502 PMID: 36776298 PMCID: PMC9909012 02/14/2023
Multi-Site Concordance of Diffusion-Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness.
(McGarry SD, Brehler M, Bukowy JD, Lowman AK, Bobholz SA, Duenweg SR, Banerjee A, Hurrell SL, Malyarenko D, Chenevert TL, Cao Y, Li Y, You D, Fedorov A, Bell LC, Quarles CC, Prah MA, Schmainda KM, Taouli B, LoCastro E, Mazaheri Y, Shukla-Dave A, Yankeelov TE, Hormuth DA 2nd, Madhuranthakam AJ, Hulsey K, Li K, Huang W, Huang W, Muzi M, Jacobs MA, Solaiyappan M, Hectors S, Antic T, Paner GP, Palangmonthip W, Jacobsohn K, Hohenwalter M, Duvnjak P, Griffin M, See W, Nevalainen MT, Iczkowski KA, LaViolette PS.) J Magn Reson Imaging. 2022 Jun;55(6):1745-1758 PMID: 34767682 PMCID: PMC9095769 SCOPUS ID: 2-s2.0-85118887092 11/13/2021
Basal Ganglia Iron Content Increases with Glioma Severity Using Quantitative Susceptibility Mapping: A Potential Biomarker of Tumor Severity.
(Reith TP, Prah MA, Choi EJ, Lee J, Wujek R, Al-Gizawiy M, Chitambar CR, Connelly JM, Schmainda KM.) Tomography. 2022 Mar 15;8(2):789-797 PMID: 35314642 PMCID: PMC8938779 SCOPUS ID: 2-s2.0-85126905772 03/23/2022
Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma.
(Amidon RF, Santos-Pinheiro F, Straza M, Prah MA, Mueller WM, Krucoff MO, Connelly JM, Kleefisch CJ, Coss DJ, Cochran EJ, Bovi JA, Schultz CJ, Schmainda KM.) Front Oncol. 2022;12:1066191 PMID: 36561526 PMCID: PMC9763264 SCOPUS ID: 2-s2.0-85144231369 12/24/2022
High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques.
(Henriksen OM, Del Mar Álvarez-Torres M, Figueiredo P, Hangel G, Keil VC, Nechifor RE, Riemer F, Schmainda KM, Warnert EAH, Wiegers EC, Booth TC.) Front Oncol. 2022;12:810263 PMID: 35359414 PMCID: PMC8961422 04/02/2022
Magnetic Resonance Imaging Mapping of Brain Tumor Burden: Clinical Implications for Neurosurgical Management: Case Report.
(Connelly JM, Prah MA, Santos-Pinheiro F, Mueller W, Cochran E, Schmainda KM.) Neurosurg Open. 2021 Dec;2(4):okab029 PMID: 34661110 PMCID: PMC8508085 10/19/2021
Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET.
(Huang S, Michalek JE, Reardon DA, Wen PY, Floyd JR, Fox PT, Clarke GD, Jerabek PA, Schmainda KM, Muzi M, Hyun H, Lee EQ, Brenner AJ.) Sci Rep. 2021 Apr 07;11(1):7632 PMID: 33828310 PMCID: PMC8027395 SCOPUS ID: 2-s2.0-85104042152 04/09/2021
Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.
(Schmainda KM, Prah MA, Marques H, Kim E, Barboriak DP, Boxerman JL.) Neuro Oncol. 2021 Feb 25;23(2):314-323 PMID: 32678438 PMCID: PMC7906067 SCOPUS ID: 2-s2.0-85102322282 07/18/2020
High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 2: Spectroscopy, Chemical Exchange Saturation, Multiparametric Imaging, and Radiomics.
(Booth TC, Wiegers EC, Warnert EAH, Schmainda KM, Riemer F, Nechifor RE, Keil VC, Hangel G, Figueiredo P, Álvarez-Torres MDM, Henriksen OM.) Front Oncol. 2021;11:811425 PMID: 35340697 PMCID: PMC8948428 03/29/2022
Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
(Bovi JA, Prah MA, Retzlaff AA, Schmainda KM, Connelly JM, Rand SD, Marszalkowski CS, Mueller WM, Siker ML, Schultz CJ.) Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):979-986 PMID: 32599030 PMCID: PMC8655709 SCOPUS ID: 2-s2.0-85089292279 07/01/2020
Human Fetal Tissue from Elective Abortions in Research and Medicine: Science, Ethics, and the Law.
(Lee TS, Feeney MB, Schmainda KM, Sherley JL, Prentice DA.) Issues Law Med. 2020;35(1):3-61 PMID: 33950608 SCOPUS ID: 2-s2.0-85105541954 05/06/2021